Abstract：
Aortitis is a rare adverse event of granulocyte colony-stimulating factor (G-CSF) treatment. Several previous studies have described recurrent aortitis caused by re-administration of the same G-CSF. However, no previous studies have examined the safety of switching between short-acting G-CSFs in patients who develop aortitis. We report the case of a 55-year-old man with refractory diffuse large B-cell lymphoma, who developed G-CSF-associated aortitis. The aortitis was triggered by filgrastim and recurred after treatment with lenograstim. The patient possessed human leukocyte antigen B52, which has been implicated in Takayasu arteritis. In addition, a drug-induced lymphocyte stimulation test for lenograstim performed upon detection of recurrent G-CSF-associated aortitis produced a positive result. Our case suggests that switching from one short-acting G-CSF to another does not prevent recurrence of G-CSF-associated aortitis. Although the etiology of G-CSF-associated aortitis has not been fully elucidated, our case also suggests that some patients may be genetically predisposed to aortitis.
摘要：
主动脉炎是粒细胞集落刺激因子（G-CSF）治疗的罕见不良事件。先前的几项研究已经描述了由再次施用相同的G-CSF引起的复发性主动脉炎。然而,以前没有研究对发生主动脉炎的患者在短效G-CSF之间转换的安全性进行过研究.我们报道了一例55岁男性难治性弥漫性大B细胞淋巴瘤，谁发展G-CSF相关的主动脉炎。非格司亭引发主动脉炎，用来诺格司亭治疗后复发。该患者具有人白细胞抗原B52，该抗原与大动脉炎有关。此外,在检测到复发的G-CSF相关性主动脉炎后进行的来诺格司亭药物诱导的淋巴细胞刺激试验产生了阳性结果.我们的病例表明，从一种短效G-CSF转换为另一种短效G-CSF并不能防止G-CSF相关主动脉炎的复发。尽管G-CSF相关性主动脉炎的病因尚未完全阐明，我们的病例还表明，一些患者可能具有主动脉炎的遗传倾向。
